Isaac Beshay, MD
Family Medicine · Costa Mesa, CANPI 1962434241
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,561 of the $17,096 with a category attached, or 85.2%. It is spread thinly across 56 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $5,296 and has fallen 63.7% since, to $1,921 in 2025. Among family medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 593 payments — averaging $28.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$3K
- AstraZeneca$2K
- AbbVie$1K
- Lilly USA, LLC$1K
- Novo Nordisk$982
- Astellas Pharma US Inc$859
- plus $7K from 50 others
Across 1,731 payments — averaging $844.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$1000K
- AbbVie$357K
- AstraZeneca$46K
- Kowa Research Institute, Inc.$26K
- Bristol Myers Squibb$24K
- Gilead$7K
- plus $2K from 1 others
What the payments were for
- Travel & lodging$2,21813%
- Food & beverage$14,56185%
- Education$3172%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,096 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 162 | $169,047 |
| FarxigaDapagliflozin Propanediol | 120 | $83,240 |
| MounjaroTirzepatide | 73 | $75,711 |
| JardianceEmpagliflozin | 85 | $73,210 |
| Xeljanz XrTofacitinib Citrate | 11 | $60,127 |
| TrulicityDulaglutide | 52 | $56,515 |
| EliquisApixaban | 58 | $55,092 |
| JanuviaSitagliptin Phosphate | 54 | $42,972 |
| XareltoRivaroxaban | 32 | $26,546 |
| ViberziEluxadoline | 13 | $25,791 |
| Metformin Er GastricMetformin Hcl | 12 | $22,041 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 28 | $21,416 |
| Nurtec OdtRimegepant Sulfate | 17 | $20,701 |
| Repatha SureclickEvolocumab | 14 | $15,921 |
| MyrbetriqMirabegron | 28 | $15,721 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $982 | $169,047162 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,325 | $132,226125 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,110 | $95,588140 claims |
| MerckJanuvia, Janumet Xr, Janumet, Belsomra | $134 | $79,982111 claims |
| PfizerEliquis, Nurtec Odt | $604 | $75,79375 claims |
| Boehringer IngelheimJardiance | $561 | $73,21085 claims |
| AbbVieViberzi, Linzess | $1,367 | $40,12942 claims |
| Johnson & JohnsonXarelto | $314 | $26,54632 claims |
| Astellas Pharma US IncMyrbetriq | $859 | $15,72128 claims |
| NovartisEntresto | $330 | $14,85022 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $113 | $11,46611 claims |
| GSKTrelegy Ellipta | $551 | $6,89011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Costa Mesa
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.